Status:
COMPLETED
Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
Lead Sponsor:
Duke University
Conditions:
Primary Brain Tumor
Brain Metastases, Adult
Eligibility:
All Genders
30-65 years
Brief Summary
Recent research indicates that variability in cognitive function for brain tumor survivors may be explained by differences in cognitive reserve (CR) and use of compensatory strategies.However, it is u...
Detailed Description
Cognitive impairments experienced by cancer survivors, from time of diagnosis through the health trajectory, are distressing, persistent, and negatively impact everyday function and quality of life. W...
Eligibility Criteria
Inclusion
- Aged 30-65 years,
- Newly diagnosed with primary brain tumor or secondary brain metastases
- Able to read and write English as the neurocognitive testing will be administered using English language forms
Exclusion
- Those with \>moderate cognitive impairment (Mini-Mental Status Examination \[MMSE\] score\<24) at baseline
- Aphasia
- Other neurodegenerative disorders Drink 3 or more alcoholic beverages per day (per Centers for Disease Control definition), report current use of illicit drugs/misuse of prescription medication, or currently undergoing treatment or had previous treatment for substance abuse at any time period (alcoholism or drug abuse).
Key Trial Info
Start Date :
July 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04075370
Start Date
July 22 2021
End Date
December 31 2022
Last Update
January 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710